Product Categories
| Country: | China |
|---|---|
| Tel: | 020-020-29185636 |
| Mobile: | 18802035152 |
| E-mail: | |
| QQ: | |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| Mortality; Evaluation of median lethal concentration (LC50). | Details |
| Median lethal concentration | Details |
| Genetic engineering animal model | Details |
| Genetically modified animal model | Details |
| Should we experiment with animals | Details |
| Animal experiment of depression | Details |
| Animal model of depression | Details |
| Factors affecting animal models | Details |
| Why do experiments with animals | Details |
| Carry out appropriate toxicity tests with experimental animals | Details |
| Comet experiment; Genotoxicity evaluation. | Details |
| Genotoxicity | Details |
| The incidence of renal capsule edema;. | Details |
| Cardiovascular toxicity heart rate; Heart rhythm; The incidence of pericardial edema; Incidence of bleeding; Incidence of changes in blood flow velocity; Incidence of thrombosis | Details |
| Fluorescence signal intensity of apoptotic cells (AO staining, TUNEL staining) | Details |
| Fluorescence signal intensity of apoptotic cells in central nervous system; | Details |
| Incidence of developmental toxicity and teratogenicity (brain, jaw, eye, kidney, intestine, trunk / tail / spinal cord / somite, body coloring, circulatory system, body edema, bleeding) | Details |
| Vitellogenin (VTG) content detection; The expression of genes related to hypothalamic pituitary gonadal axis was detected. | Details |
| Peripheral motor nerve length; Incidence of brain degeneration; | Details |
| Number of hematotoxic neutrophils; Number of macrophages; Number of red blood cells (signal intensity); Blood flow. | Details |
| Degree of liver degeneration; Yolk sac size. | Details |
| Reproductive toxicity and reproductive ability evaluation; Gonadal growth evaluation; Histological sections of gonads; | Details |
| apoptotic cell | Details |
| Incidence of acute toxicity (brain, jaw, eye, kidney, intestine, trunk / tail / spinal cord / somite, body coloring, circulatory system, body edema, bleeding) | Details |
| Anaphylactic reaction | Details |
| inflammatory reaction | Details |
| Number of neutrophils; Expression level of inflammatory factors. | Details |
| Ocular toxicity | Details |
| Eye size; Ocular apoptotic cells; Ocular vascular area; Ocular histopathology. | Details |
| Gastrointestinal toxicity | Details |
| Tryptase expression level (OD value); Anaphylactic reaction test. | Details |
| Intestinal morphology; Intestinal peristalsis requires motor function. | Details |
| Skin toxicity | Details |
| Phenotypic observation | Details |
| Nephrotoxicity | Details |
| Audiotoxicity | Details |
| Fluorescence signal intensity of hair cells | Details |
| Bone mineral density (fluorescence signal intensity); Number of vertebrae. | Details |
| Behavior (touch response, movement influence, light and dark influence); | Details |
| Hepatotoxicity (juvenile fish) | Details |
| Gastrointestinal peristalsis function (autonomic nerve). | Details |
| Behavior | Details |
| Immunotoxicity | Details |
| Skin irritation; Muscle texture; Quantification of skin apoptotic cells; Skin pigment changes. | Details |
| Carcinogenicity (mice) | Details |
| Macrophage function | Details |
| Osteotoxicity | Details |
| Behavioral toxicity | Details |
| neurotoxicity | Details |
| Platelet aggregation thrombosis model | Details |
| Protective model of vascular endothelial injury | Details |
| Myocardial injury protective agent screening model | Details |
| Spleen yang deficiency model | Details |
| Oxygen free radical (ROS) scavenger screening model | Details |
| Induced qi stagnation and blood stasis thrombosis model | Details |
| PM2. 5. Screening model of drainage promoters | Details |
| Mitochondrial function | Details |
| Intestinal mucus secretion function | Details |
| Induction model of high sugar and high fat diet | Details |
| Hypolipidemic model | Details |
| Pharmacodynamic evaluation model of slimming drugs | Details |
| Screening model of gastrointestinal motility inhibitors | Details |
| Uric acid model | Details |
| Fat metabolism model | Details |
| Screening model of energy metabolism regulator | Details |
| Screening model of antialcoholic agents | Details |
| Screening model of P-glycoprotein inhibitors | Details |
| Metabolic system | Details |
| Induction model of caspase activity | Details |
| Efficacy evaluation model of drug efficacy evaluation system | Details |
| Anti angiogenesis model | Details |
| Apoptosis inhibitor screening model | Details |
| Angiogenesis inhibitor screening | Details |
| Safety evaluation | Details |
| Preclinical drug experiment preclinical research (outsourcing entrusted experiment) | Details |
| Drug evaluation and testing items (outsourcing entrusted experiment) | Details |
| Preclinical spinal cord injury experiment | Details |
| Preclinical evaluation of reproductive toxicity | Details |
| Preclinical evaluation of antiviral research and development | Details |
| Preclinical evaluation of cardiac drugs | Details |
| mycoalert mycoplasma detection kit | Details |
| Intestinal digestive function | Details |
| Screening model of angiogenesis promoters | Details |
| Erythrocyte thrombosis model | Details |
| Cardio cerebrovascular | Details |
| Mouse bradycardia model | Details |
| Drug screening model for the treatment of heart failure | Details |
| Screening model of renal protective agents | Details |
| Screening model of hepatoprotective drugs | Details |
| Liver kidney model | Details |
| Cytochrome P450 analysis | Details |
| Screening model of bone development promoters | Details |
| Skeletal muscle | Details |
| Drug safety evaluation model index | Details |
| Cartilage injury model | Details |
| Analgesic drug screening | Details |
| Promoting tissue regeneration / wound healing | Details |
| Screening model of therapeutic agents for osteoporosis | Details |
| Embryotoxicity (OECD standard) | Details |
| The incidence of egg coagulation; No heart rate; Hatching rate; The incidence of no somite formation; Incidence of tail non separation; | Details |
| Product Total： Product Page： | ||||
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 | ||||